INmune Bio (Nasdaq:INMB) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

INMB Stoklara Genel Bakış

Klinik aşamada bir immünoloji şirketi olan INmune Bio, Inc, Amerika Birleşik Devletleri'nde hastalıkları tedavi etmek için hastaların doğuştan gelen bağışıklık sistemini yeniden programlayacak ilaçlar geliştirmeye odaklanmaktadır.

Şirket hakkında

INMB temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 78.19% oranında artması öngörülüyor

Analistler hisse senedi fiyatının 259.3% oranında artacağı konusunda hemfikir

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $85K )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

INmune Bio, Inc. Rakipler

CervoMed

NasdaqCM:CRVO

US$111.1m

Decibel Therapeutics

NasdaqGS:DBTX

US$124.3m

Kinnate Biopharma

NasdaqGS:KNTE

US$125.1m

Nuvectis Pharma

NasdaqCM:NVCT

US$113.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti INmune Bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$5.31
52 Haftanın En Yüksek Seviyesi	US$14.74
52 Haftanın En Düşük Seviyesi	US$4.81
Beta	1.85
11 Aylık Değişim	-9.69%
3 Aylık Değişim	-36.71%
1 Yıllık Değişim	-22.59%
33 Yıllık Değişim	-71.19%
5 Yıllık Değişim	49.16%
Halka arzdan bu yana değişim	-33.54%

Son Haberler & Güncellemeler

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 30

Recent updates

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 30

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

Jul 12

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Apr 05

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Mar 25

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

Dec 02

INmune Bio A No-Brainer Investment

Oct 13

Hissedar Getirileri

	INMB	US Biotechs	US Pazar
7D	-3.6%	-1.1%	0.6%
1Y	-22.6%	17.1%	30.3%

Getiri vs. Endüstri: INMB geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: INMB geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is INMB's price volatile compared to industry and market?
INMB volatility
INMB Average Weekly Movement	10.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: INMB son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: INMB 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	14	RJ Tesi	www.inmunebio.com

Klinik aşamada bir immünoloji şirketi olan INmune Bio, Inc, Amerika Birleşik Devletleri'nde hastalığı tedavi etmek için hastaların doğuştan gelen bağışıklık sistemini yeniden programlayacak ilaçlar geliştirmeye odaklanmaktadır. Hematolojik maligniteleri, solid tümörleri ve kronik enflamasyonu tedavi etmek için ürün adayları geliştirmeyi ve ticarileştirmeyi amaçlamaktadır. Şirketin geliştirme programları arasında yüksek riskli miyelodisplastik sendromlu hastaların tedavisi için Faz 1'de olan INKmune; ve MUC4 eksprese eden HER2+ meme kanserli kadınlar ve diğer MUC4 dirençli kanserler de dahil olmak üzere immünoterapiye dirençli görünen bazı epitelyal kanser hücrelerinin yüzeyindeki müsinöz bir poliglukan olan INB03 yer almaktadır.

INmune Bio, Inc. Temel Bilgiler Özeti

INmune Bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
INMB temel i̇stati̇sti̇kler
Piyasa değeri	US$115.79m
Kazançlar(TTM)	-US$37.74m
Gelir(TTM)	US$85.00k

1,380x

P/S Oranı

-3.1x

F/K Oranı

INMB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
INMB gelir tablosu (TTM)
Gelir	US$85.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$85.00k
Diğer Giderler	US$37.83m
Kazançlar	-US$37.74m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.71
Brüt Marj	100.00%
Net Kâr Marjı	-44,402.35%
Borç/Özkaynak Oranı	13.4%

INMB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

INMB Stoklara Genel Bakış

Ödüller

Risk Analizi

INmune Bio, Inc. Rakipler

NasdaqCM:CRVO

US$111.1m

NasdaqGS:DBTX

US$124.3m

NasdaqGS:KNTE

US$125.1m

NasdaqCM:NVCT

US$113.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

CFO, Treasurer & Secretary recently bought US$53k worth of stock

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Co-Founder recently bought US$98k worth of stock

INmune Bio, Inc. Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Recent updates

CFO, Treasurer & Secretary recently bought US$53k worth of stock

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Co-Founder recently bought US$98k worth of stock

INmune Bio, Inc. Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio, Inc. has filed a Follow-on Equity Offering.

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus EPS estimates upgraded to US$2.26 loss

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™? on Proteins That Regulation Synapse in Alzheimer's Patients

INmune Bio, Inc. to Report Q2, 2024 Results on Aug 01, 2024

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.67 loss per share (vs US$1.52 loss in FY 2022)

Consensus EPS estimates fall by 24%

INmune Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million.

Independent Director recently bought US$246k worth of stock

Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024

INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program

New minor risk - Share price stability

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA

Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Consensus revenue estimates increase by 30%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line

INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference

INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Consensus revenue estimates increase by 51%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer

Insufficient new directors

INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Price target decreased to US$14.33